And that is exactly how this one is playing out. There is still plenty of market need for the Edwards LifeSciences of the world. . . but it too may eventually be on JNJ's shoppin' list. [Just a word, to those looking ahead, for M&A gainsplay. . . .]
Here is the latest on all that, from JNJ's MedTech division, itself (but with the renewed vigor of the DoJ's Antitrust desk in evidence, I might ease off the "market leadership" type boastings):
. . . .[JNJ's MedTech unit] announced it entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies’ boards of directors. . . .
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD). The transaction follows Johnson & Johnson MedTech’s successful acquisitions of Abiomed, a leader in heart recovery, and more recently Laminar, an innovator in left atrial appendage elimination for patients with non-valvular atrial fibrillation (AFib). These acquisitions complement and build on Johnson & Johnson’s established global leadership position in electrophysiology through the Biosense Webster portfolio. . . .
So it goes -- with all my NCAA picks turning up roses -- and the Kentucky Derby not too far off, now. Smile.
नमस्ते
No comments:
Post a Comment